JP2023055871A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023055871A5 JP2023055871A5 JP2023014793A JP2023014793A JP2023055871A5 JP 2023055871 A5 JP2023055871 A5 JP 2023055871A5 JP 2023014793 A JP2023014793 A JP 2023014793A JP 2023014793 A JP2023014793 A JP 2023014793A JP 2023055871 A5 JP2023055871 A5 JP 2023055871A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- use according
- composition
- antibody
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024189529A JP2025016606A (ja) | 2014-09-16 | 2024-10-29 | 抗nkg2a抗体を使用した治療計画 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462050948P | 2014-09-16 | 2014-09-16 | |
| US62/050,948 | 2014-09-16 | ||
| US201462067642P | 2014-10-23 | 2014-10-23 | |
| US62/067,642 | 2014-10-23 | ||
| US201462083929P | 2014-11-25 | 2014-11-25 | |
| US62/083,929 | 2014-11-25 | ||
| US201462093124P | 2014-12-17 | 2014-12-17 | |
| US201462093141P | 2014-12-17 | 2014-12-17 | |
| US62/093,124 | 2014-12-17 | ||
| US62/093,141 | 2014-12-17 | ||
| JP2020166883A JP2021008487A (ja) | 2014-09-16 | 2020-10-01 | 抗nkg2a抗体を使用した治療計画 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020166883A Division JP2021008487A (ja) | 2014-09-16 | 2020-10-01 | 抗nkg2a抗体を使用した治療計画 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024189529A Division JP2025016606A (ja) | 2014-09-16 | 2024-10-29 | 抗nkg2a抗体を使用した治療計画 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023055871A JP2023055871A (ja) | 2023-04-18 |
| JP2023055871A5 true JP2023055871A5 (cg-RX-API-DMAC10.html) | 2023-08-08 |
| JP7580506B2 JP7580506B2 (ja) | 2024-11-11 |
Family
ID=54105801
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017514485A Pending JP2017538660A (ja) | 2014-09-16 | 2015-09-15 | 抗nkg2a抗体を使用した治療計画 |
| JP2020166883A Pending JP2021008487A (ja) | 2014-09-16 | 2020-10-01 | 抗nkg2a抗体を使用した治療計画 |
| JP2023014793A Active JP7580506B2 (ja) | 2014-09-16 | 2023-02-02 | 抗nkg2a抗体を使用した治療計画 |
| JP2024189529A Pending JP2025016606A (ja) | 2014-09-16 | 2024-10-29 | 抗nkg2a抗体を使用した治療計画 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017514485A Pending JP2017538660A (ja) | 2014-09-16 | 2015-09-15 | 抗nkg2a抗体を使用した治療計画 |
| JP2020166883A Pending JP2021008487A (ja) | 2014-09-16 | 2020-10-01 | 抗nkg2a抗体を使用した治療計画 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024189529A Pending JP2025016606A (ja) | 2014-09-16 | 2024-10-29 | 抗nkg2a抗体を使用した治療計画 |
Country Status (13)
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3409289T1 (sl) | 2010-02-26 | 2020-12-31 | Novo Nordisk A/S | Stabilni sestavki, ki vsebujejo protitelo |
| MX342131B (es) | 2011-06-17 | 2016-09-14 | Novo Nordisk As | Eliminacion selectiva de celulas erosivas. |
| KR20250007689A (ko) | 2014-09-16 | 2025-01-14 | 이나뜨 파르마 에스.에이. | 림프구에서의 억제 경로의 중화 |
| AU2015316993B2 (en) | 2014-09-16 | 2021-03-18 | Innate Pharma | Treatment regimens using anti-NKG2A antibodies |
| EP3209687A1 (en) | 2014-10-23 | 2017-08-30 | Innate Pharma | Treatment of cancers using anti-nkg2a agents |
| EP3297672B1 (en) | 2015-05-21 | 2021-09-01 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| EP3325967B1 (en) | 2015-07-24 | 2019-12-04 | Innate Pharma | Methods for detecting tissue infiltrating nk cells |
| SMT202100280T1 (it) | 2016-01-21 | 2021-07-12 | Innate Pharma | Neutralizzazione delle vie inibitorie nei linfociti |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| WO2018073363A1 (en) | 2016-10-21 | 2018-04-26 | Innate Pharma | Treatment with anti-kir3dl2 agents |
| SG10202107880XA (en) | 2017-05-12 | 2021-09-29 | Harpoon Therapeutics Inc | Mesothelin binding proteins |
| WO2019011852A1 (en) * | 2017-07-10 | 2019-01-17 | Innate Pharma | POLYTHERAPY USING ANTIBODY AGAINST SIGLEC-9 HUMAN AND ANTIBODY AGAINST NKG2A HUMAN FOR THE TREATMENT OF CANCER |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| CA3078969A1 (en) | 2017-10-13 | 2019-04-18 | Harpoon Therapeutics, Inc. | Trispecific proteins and methods of use |
| TWI924623B (zh) | 2018-03-13 | 2026-05-11 | 法商天賜製藥公司 | 頭頸癌之治療 |
| JP7351845B2 (ja) | 2018-03-23 | 2023-09-27 | ブリストル-マイヤーズ スクイブ カンパニー | Micaおよび/またはmicbに対する抗体ならびにそれらの使用 |
| WO2019219658A1 (en) | 2018-05-15 | 2019-11-21 | Medimmune Limited | Treatment of cancer |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| CN119306844A (zh) | 2018-09-25 | 2025-01-14 | 哈普恩治疗公司 | Dll3结合蛋白及使用方法 |
| EP3878869A4 (en) * | 2018-11-07 | 2023-04-19 | Shanghai Hyamab Biotech Co., Ltd. | NKG2A ANTIBODIES, METHOD OF PRODUCTION THEREOF AND USE THEREOF |
| MX2021005708A (es) | 2018-11-16 | 2021-09-21 | Bristol Myers Squibb Co | Anticuerpos anti grupo 2a del receptor inhibidor de células asesinas naturales (anti-nkg2a) y usos de los mismos. |
| WO2020205440A1 (en) * | 2019-03-29 | 2020-10-08 | Dren Bio, Inc. | Methods of reducing large granular lymphocyte and natural killer cell levels |
| US20220363760A1 (en) | 2019-05-30 | 2022-11-17 | Bristol-Myers Squibb Company | Multi-tumor gene signature for suitability to immuno-oncology therapy |
| WO2020243570A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Cell localization signature and combination therapy |
| JP2022534982A (ja) | 2019-05-30 | 2022-08-04 | ブリストル-マイヤーズ スクイブ カンパニー | 細胞局在化シグネチャーおよびその使用 |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| WO2021090146A1 (en) | 2019-11-04 | 2021-05-14 | Astrazeneca Ab | Combination therapy for treating cancer |
| WO2021219048A1 (zh) * | 2020-04-30 | 2021-11-04 | 迈威(上海)生物科技股份有限公司 | 一种靶向nkg2a和pd-l1的双特异性抗体及应用 |
| CN116096754A (zh) * | 2020-05-04 | 2023-05-09 | 免疫里森公司 | 前体三特异性抗体构建体及其使用方法 |
| JP2023525049A (ja) * | 2020-05-08 | 2023-06-14 | シアトル・チルドレンズ・ホスピタル・ドゥーイング/ビジネス/アズ・シアトル・チルドレンズ・リサーチ・インスティテュート | ナチュラルキラー細胞を標的とするキメラ抗原受容体(car) |
| CN116234568A (zh) | 2020-07-07 | 2023-06-06 | 生物技术公司 | 用于hpv阳性癌症的治疗性rna |
| CN116194125A (zh) * | 2020-08-07 | 2023-05-30 | 克莱格医学有限公司 | 工程化改造的细胞以及工程化改造细胞的方法 |
| IL300916A (en) | 2020-08-31 | 2023-04-01 | Bristol Myers Squibb Co | Cell localization signature and immunotherapy |
| EP4221752A4 (en) | 2020-09-30 | 2024-12-04 | Dren Bio, Inc. | ANTI-CD94 ANTIBODIES AND METHODS OF USE THEREOF |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| TW202241935A (zh) | 2020-12-18 | 2022-11-01 | 美商世紀治療股份有限公司 | 具有可調適受體專一性之嵌合抗原受體系統 |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性rna |
| PT4267105T (pt) | 2020-12-28 | 2025-04-30 | Bristol Myers Squibb Co | Composições de anticorpos e métodos de utilização das mesmas |
| AU2021416156A1 (en) | 2020-12-28 | 2023-06-22 | Bristol-Myers Squibb Company | Methods of treating tumors |
| JP2024514530A (ja) | 2021-04-02 | 2024-04-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 切断型cdcp1に対する抗体およびその使用 |
| CA3222040A1 (en) * | 2021-06-01 | 2022-12-08 | Les Laboratoires Servier | Anti-nkg2a antibodies and compositions |
| WO2023285552A1 (en) | 2021-07-13 | 2023-01-19 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| US20250206775A1 (en) | 2022-03-18 | 2025-06-26 | Bristol-Myers Squibb Company | Methods of isolating polypeptides |
| AU2023281061A1 (en) | 2022-06-02 | 2024-12-05 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
| JP2026501506A (ja) | 2022-12-14 | 2026-01-16 | アステラス・ファーマ・ヨーロッパ・ベスローデン・フェンノートシャップ | Cldn18.2及びcd3に結合する二重特異性結合剤並びに免疫チェックポイント阻害剤を含む併用療法 |
| WO2024150017A1 (en) | 2023-01-13 | 2024-07-18 | Akrivia Biomedics Limited | Method of profiling diseases |
| WO2024196952A1 (en) | 2023-03-20 | 2024-09-26 | Bristol-Myers Squibb Company | Tumor subtype assessment for cancer therapy |
| CN121712571A (zh) | 2023-08-15 | 2026-03-20 | 百时美施贵宝公司 | 陶瓷羟基磷灰石色谱流通法 |
| WO2026033885A1 (en) | 2024-08-08 | 2026-02-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| AR134560A1 (es) | 2023-12-08 | 2026-01-28 | Astellas Pharma Inc | Terapia de combinación que implica agentes de unión biespecíficos que se unen a cldn18.2 y cd3 y agentes que estabilizan o aumentan la expresión de cldn18.2 |
| WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| CN122459678A (zh) | 2023-12-29 | 2026-07-24 | 百时美施贵宝公司 | KRAS抑制剂与Treg耗竭剂的组合疗法 |
| NL2037811B1 (en) | 2024-05-29 | 2025-12-12 | Univ Oslo | Treatment for Cancer |
| GB202417285D0 (en) | 2024-11-25 | 2025-01-08 | Univ Oxford Innovation Ltd | Expanded t cell population |
| GB202418460D0 (en) | 2024-12-16 | 2025-01-29 | Univ Oxford Innovation Ltd | Multivalent binding proteins |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9725764D0 (en) | 1997-12-04 | 1998-02-04 | Isis Innovation | HLA-E binding |
| US20030095965A1 (en) | 2001-05-02 | 2003-05-22 | Katrien Van Beneden | Antibodies to Ly49E and CD94/NKG2 receptors |
| RU2481356C2 (ru) | 2004-12-28 | 2013-05-10 | Иннейт Фарма | Моноклональные антитела против nkg2a |
| CN101107269B (zh) * | 2004-12-28 | 2012-10-31 | 依奈特制药公司 | 抗nkg2a的单克隆抗体 |
| DK2038306T3 (en) | 2006-06-30 | 2015-03-09 | Novo Nordisk As | ANTI-NKG2A ANTIBODIES AND APPLICATIONS THEREOF |
| MX2010007935A (es) | 2008-01-24 | 2010-08-23 | Novo Nordisk As | Anticuerpo monoclonal humanizado anti-nkg2a humano. |
| US20110033389A1 (en) | 2009-04-29 | 2011-02-10 | Zhifeng Chen | Modified antibodies for passive immunotherapy |
| SI3409289T1 (sl) | 2010-02-26 | 2020-12-31 | Novo Nordisk A/S | Stabilni sestavki, ki vsebujejo protitelo |
| MX342131B (es) * | 2011-06-17 | 2016-09-14 | Novo Nordisk As | Eliminacion selectiva de celulas erosivas. |
| RU2017105425A (ru) | 2014-08-28 | 2018-09-28 | Академиш Зикенхёйс Лейден Х.О.Д.Н. Люмк | Комбинации антитела против cd94/nkg2a и/или cd94/nkg2b и вакцины |
| AU2015316993B2 (en) | 2014-09-16 | 2021-03-18 | Innate Pharma | Treatment regimens using anti-NKG2A antibodies |
| KR20250007689A (ko) | 2014-09-16 | 2025-01-14 | 이나뜨 파르마 에스.에이. | 림프구에서의 억제 경로의 중화 |
| EP3209687A1 (en) * | 2014-10-23 | 2017-08-30 | Innate Pharma | Treatment of cancers using anti-nkg2a agents |
| SMT202100280T1 (it) | 2016-01-21 | 2021-07-12 | Innate Pharma | Neutralizzazione delle vie inibitorie nei linfociti |
| TWI924623B (zh) | 2018-03-13 | 2026-05-11 | 法商天賜製藥公司 | 頭頸癌之治療 |
| WO2019219658A1 (en) | 2018-05-15 | 2019-11-21 | Medimmune Limited | Treatment of cancer |
-
2015
- 2015-09-15 AU AU2015316993A patent/AU2015316993B2/en active Active
- 2015-09-15 PL PL15763016T patent/PL3193929T3/pl unknown
- 2015-09-15 KR KR1020247031251A patent/KR20240141862A/ko active Pending
- 2015-09-15 SG SG11201701387SA patent/SG11201701387SA/en unknown
- 2015-09-15 CN CN201580050103.1A patent/CN107074950A/zh active Pending
- 2015-09-15 DK DK15763016.1T patent/DK3193929T3/da active
- 2015-09-15 KR KR1020177008837A patent/KR20170068458A/ko not_active Ceased
- 2015-09-15 US US15/511,792 patent/US10676523B2/en active Active
- 2015-09-15 HU HUE15763016 patent/HUE044704T2/hu unknown
- 2015-09-15 ES ES15763016T patent/ES2742456T3/es active Active
- 2015-09-15 JP JP2017514485A patent/JP2017538660A/ja active Pending
- 2015-09-15 WO PCT/EP2015/071073 patent/WO2016041947A1/en not_active Ceased
- 2015-09-15 SG SG10202007781TA patent/SG10202007781TA/en unknown
- 2015-09-15 EP EP15763016.1A patent/EP3193929B1/en active Active
-
2017
- 2017-02-19 IL IL250672A patent/IL250672B/en active IP Right Grant
-
2020
- 2020-06-08 US US16/894,937 patent/US20200299383A1/en not_active Abandoned
- 2020-10-01 JP JP2020166883A patent/JP2021008487A/ja active Pending
-
2021
- 2021-04-08 US US17/225,160 patent/US12037392B2/en active Active
- 2021-06-07 AU AU2021203744A patent/AU2021203744B2/en active Active
-
2023
- 2023-02-02 JP JP2023014793A patent/JP7580506B2/ja active Active
-
2024
- 2024-07-15 US US18/772,517 patent/US20240368281A1/en active Pending
- 2024-10-29 JP JP2024189529A patent/JP2025016606A/ja active Pending
-
2025
- 2025-07-17 AU AU2025205563A patent/AU2025205563A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025016606A5 (cg-RX-API-DMAC10.html) | ||
| KR101905208B1 (ko) | Cd38을 특이적으로 인식하는 항체 및 보르테조밉을 함유하는 항종양 조합물 | |
| TWI436770B (zh) | 包含專一性辨識cd38之抗體及阿糖胞苷(cytarabine)之抗腫瘤組合 | |
| JP6215429B2 (ja) | Cd38を特異的に認識する抗体とシクロホスファミドとを含有する抗腫瘍組合せ | |
| TWI454260B (zh) | 包含專一性辨識cd38之抗體及黴法蘭(melphalan)之抗腫瘤組合 | |
| JP2009518441A5 (cg-RX-API-DMAC10.html) | ||
| JP2021512107A5 (cg-RX-API-DMAC10.html) | ||
| JP2024537288A5 (cg-RX-API-DMAC10.html) | ||
| JP2023506779A5 (cg-RX-API-DMAC10.html) | ||
| HK1164154B (en) | Antitumor combinations containing antibodies recognizing specifically cd38 and cylophosphamide | |
| HK1164165B (en) | Antitumor combinations containing antibodies recognizing specifically cd38 and melphalan |